AD Pipeline Watch: CAGE Bio Initiates Phase 2b Trial for CGB-500, a Topical JAK Inhibitor for Moderate to Severe AD
CAGE Bio, Inc. is initiating a Phase 2b dose-ranging trial for its CGB-500 (1% tofacitinib), a topical Janus kinase (JAK) inhibitor ointment for moderate to severe atopic dermatitis (AD) and low body surface area (BSA) involvement. CGB-500 was developed using CAGE Bio’s proprietary ionic liquid technology. CGB-500 delivers medicine directly through the skin, with minimal […]